Unlabeled Use:
Contraindicated in:
Use Cautiously in:
CV: conduction disturbances, angina, bradycardia, hypotension, SUPRAVENTRICULAR ARRHYTHMIAS, VENTRICULAR ARRHYTHMIAS.
Derm: rash.
EENT: blurred vision.
GI: altered taste, constipation, nausea, vomiting, diarrhea, dry mouth.
Hemat: AGRANULOCYTOSIS.
MS: joint pain.
Neuro: dizziness, shaking, weakness.
Drug-Drug:
Drug-Food:
(Generic available)
Absorption: 3–11% absorbed following oral administration.
Distribution: Widely distributed to tissues.
Metabolism/Excretion: Extensively metabolized by the liver by the CYP1A2, CYP2D6, and CYP3A4 isoenzymes (some metabolites have antiarrhythmic activity); the CYP2D6 isoenzyme exhibits genetic polymorphism (7% of population may be poor metabolizers and may have significantly ↑ propafenone concentrations and an ↑ risk of adverse effects). .
Half-life: Extensive metabolizers: 2–10 hr; Slow metabolizers: 10–32 hr.
NDC Code*